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Abstract. The importance of developing of drugs which could be taken post-coitally or used
once-a-month in the case of a delay in the onset of the menses is well recognized. The 
availability of such technology would limit exposure to fertility regulating agents to such 
occasions where there is coital exposure or possibility of pregnancy.
Methods of post-coital contraception used so far include IUD's inserted post-coitally, 
estrogens, and combinations of estrogens and gestagens. These are reserved primarily for 
emergency situations to protect women from unwanted pregnancy resulting from rape or 
unprotected coitus. Levonorgestrel has shown satisfactory results in terms of contraceptive 
efficacy and is being further evaluated clinically. A number of problems inherent in the 
development of post-coital contraception are discussed.
Menstrual regulation could be achieved by a number of approaches: (a) block progesterone 
receptors and interfere with the preparation of the endometrium for implantation; 
(b) luteolysis leading to decreased progesterone levels and interruption of implantation; and 
(c) termination of early pregnancy by prostaglandins. A number of progesterone antagonists 
have been evaluated. One of the compounds, RU38486 is being evaluated clinically for 
termination of very early pregnancy.
Deglycosylated derivatives of human chorionic gonadotropin have been shown to 
antagonize the action of human chorionic gonadotropin and interfere with established 
pregnancy in rats. Appropriate methods of delivery, immunogenicity and alternate methods 
for production of human chorionic gonadotropin need to be considered before evaluation of 
the derivatives for clinical use. 
In vitro and in vivo models need to be developed for evaluation of the teratogenicity and 
embryotoxicity of post-coital and menses inducing agents.
There are a number of gaps in the knowledge of the processes regulating implantation which 
should be investigated in rodents and in different non-human primate species.
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Introduction 
 
The importance of the development of drugs which could be taken post-coitally, or 
used once-a-month in the case of a delay in the onset of menstrual cycles has been 
stressed by a number of countries (WHO Special Programme in Human Reproduction, 
Tenth Annual Report, 1981). The relative acceptance of these two approaches to birth 
control in different populations will, however, be influenced by cultural differences.
 
Post-coital agents 
 
There is a felt but as yet unmet need for safe, effective and acceptable post-coital drugs.
Methods of post-coital contraception used so far have been reserved primarily for
 
 
Abbreviations used: DES, Diethylstilbesterol; LH, luteinizing hormone; PC, post-coitum; hCG, human
chorionic gonadotropin; HF, hydrogenfluoride; DG, deglycosylated.
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‘emergency situations’ to protect women from unwanted pregnancy resulting from 
rape, a single act of unprotected coitus, failed barrier methods such as ruptured 
condoms or defective diaphragms, and for the many women who are unprotected 
because of infrequent coitus. 
A ‘post-coital pill’, by definition, is a drug which is ingested after intercourse takes 
place (but not necessarily following each coital act on any one day). One of the primary 
objectives of the post-coital approach is to limit drug exposure, particularly for women 
who do not have intercourse daily or have a limited number of coital exposures in a 
month, as compared to the presently available methods of oral contraception in which a 
tablet containing a combination of a gestagen and estrogen is taken daily for 22 days, 
long-acting gestagens in which a compound is injected intramuscularly once every two 
or three months, or IUDs which are inserted by a physician. These methods involve the 
use of a contraceptive modality unrelated to the act of coitus. Probabilities that an act 
of intercourse will lead to conception (with establishment of a pregnancy of at least six 
weeks duration) can be calculated with reference to the estimated day of ovulation. 
Using self-observed vulvar changes in the characteristics of cervical mucus, a fertile 
period can be described, in which the last day of ‘fertile-type mucus’ designated as the 
‘peak day’, has been shown to be correlated closely with the time of ovulation (Billings 
et al., 1972; Flynn and Lynch, 1976; Hilgers et al., 1978). The fertile period is defined as 
commencing on the first day of any recognizable mucus, and as ending on the evening of 
the fourth day after the peak day. In a multicentred study carried out in five centres 
from four continents, the WHO Task Force on Methods for the Determination of the 
Fertile Period (1983) has estimated that the probability of conception is low (0·004 per 
cycle) following the act of intercourse outside the fertile period. It rose to 0·024 on days 
of ‘sticky’ mucus four days or more prior to the peak day, to 0·5–0·55 in the three days 
prior to the peak. It was 0·667 on the peak day, and fell to 0·089 on the third day after the 
peak. The overall length of the fertile period in the study was 9·6 ± 2·6 (SD) days. It 
seems reasonable to aim for a post-coital pill that would be taken no more than a 
maximum of 10–12 days a month. The ultimate objective of a post-coital drug would be
to interfere with implantation, irrespective of the day of the cycle when the drug would 
be taken. A drug effective in inhibiting implantation during the most fertile period is 
likely to be effective in other periods of the cycle also.
The desirable biological profile of a post-coital drug is difficult to define, since the 
physiological events that should be interefered with are varied in different stages of the 
menstrual cycle. No single drug is likely to affect all the physiological mechanisms 
during the different phases of the menstrual cycle. Some oral contraceptives (combi- 
nations of gestagen and estrogen) are effective by inhibiting ovulation. A post-coital 
drug is intended to act, among other ways, by inhibition of the processes crucial to the 
initiation and establishment of pregnancy viz. the implantation of the blastocyst in the 
uterus. It is clear that the post-coital pill would be needed most in the periovulatory 
period when the chances of conception are highest.
The problems concerning the use of the post-coital pill are the: (a) number of times 
the pill is taken during a cycle; (b) side effects depending on the number of days of coital 
exposure and tablets taken; (c) variation of side effects according to the stage of the 
cycle (follicular, ovulatory, or luteal phase) when the pills are ingested, e.g. a compound
with gestagenic properties when taken a number of times during the luteal phase of the
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menstrual cycle may delay the onset of menstruation and result in heavy bleeding,
whereas if taken a few times during the follicular phase of the cycle it may lead to 
spotting or progesterone withdrawal bleeding.
 
Clinical studies 
 
Two approaches to post-coital contraception, used as “emergency” measures involve: 
(a) insertion of a copper containing intrauterine device, the copper T, within five days of 
unprotected coital exposure; no pregnancies were reported in a series on 97 women 
treated in this way (Lippes et al., 1976); or (b) administration of synthetic, natural or 
conjugated estrogens. Diethylstilbesterol (DES), has been used at a dose of 50 mg daily 
in divided doses for five days with a failure rate from 0 to 2·4 %. The effectiveness of this
method depends partly on its early administration, within 24–72 h after coitus 
(Kuchera, 1975). Ethinyl estradiol and other conjugated estrogens have also been 
evaluated with varying success. The action of these steroids appears to be due to 
changes in the endometrium rendering it hostile to implantation (Yuzpe, 1979). 
Synthetic estrogens like DES are no longer used and have been associated with adverse 
effects on the reproductive tract in male and female progeny (Stilman, 1982). One of the 
major handicaps in the development of post-coital drugs has been the difficulty of 
completely dissociating the oestrogenicity of available compounds from their anti- 
implantation effect. A number of non-steroidal compounds have been evaluated in 
animals in an effort to identify an effective drug having little estrogenic activity, but 
none has reached the stage of clinical trials (Harper, 1982; Prasad and Sankaran, 1975).
A combination of 200 µg of ethinyl estradiol and 2 mg of dl-norgestrel seems to be 
effective as an emergency post-coital contraceptive with several advantages over 
estrogens alone. The combination was administered either as a single dose (Van Santen 
and Haspels, 1982) or in two doses (12 h apart) after an unprotected coitus within the 
previous 72 h (Yuzpe et al., 1982). In a multicentred study involving 692 women the 
pregnancy rate was 1·6%; no serious side effects other than nausea/vomiting were
encountered and menstrual bleeding occurred in more than 98 % of treated subjects 
within 21 days after treatment. Because of the potential failure rate and unpredictability 
of ensuring menstrual bleeding, Yuzpe et al. (1982) suggest that the method be reserved 
as an emergency post-coital contraceptive only.
Randomized double-blind studies are necessary to further compare the efficacy of 
this form of therapy with ethinyl estradiol or conjugated estrogen employed alone. It 
has been speculated that the combination acts either by: (a) suppressing ovulation: 
(b) disrupting luteal function by acting directly on the corpus luteum; or (c) interfering 
with appropriate endometrial responses to ovarian steroids.
 
Progestins 
 
The two most frequently used compounds include d-norgestrel and quingestanol 
acetate (Mischler et al., 1974); the latter is no longer in use.
Post-coital administration of levonorgestrel has shown satisfactory results in terms 
of contraceptive efficacy, tolerance and acceptability. A dose-response relationship has 
been reported in a number of studies (Kesseru et al., 1974; Kovacs et al., 1979); the use of 
150 µg dose was associated with a high failure rate, whereas 750 µg of levonorgestrel
administered within 3 h after coital exposure was highly effective as a contraceptive
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(Farkas, 1978); four pregnancies occurred in a two and a half year study involving 111 
women treated during 999 cycles. In another study, when the drug was administered 
after coitus only during the periovulatory period in 50 women (150 cycles), there was no 
pregnancy (Kovacs et al., 1979). Although the study does not reflect on the real-life 
situation, i.e. restricting coitus only to the periovulatory period, it does indicate the 
efficacy of the drug when administered during the most fertile period. Levonorgestrel 
(Postinor) is marketed in Hungary as a post-coital drug, subject to a maximum intake 
of four tablets (each of 750 µg) a month, i.e. 3 mg/total dose/month. Depending on the 
dose employed, nausea and vomiting, headache, dizziness and breast tenderness have 
been reported. However, one of the most frequent problems is the alteration in the 
menstrual pattern produced by the progestin. Irregular menstrual bleeding does not 
appear to be acceptable to many cultures, and if amenorrhoea results, it is necessary to 
rule out the possibility of pregnancy before continued use of the progestin. The WHO is 
carrying out a multicentre study in eight countries to evaluate the post-coital efficacy of 
750 µg of levonorgestrel when administered during the periovulatory or fertile period 
only. The other objectives of the study are (a) to assess the side-effects of the drug and 
to correlate these, if possible, with the dose of the drug administered, as well as the 
timing of its administration in relation to the menstrual cycle, and (b) determine the- 
acceptability of such a regime (WHO Special Programme of Research in Human 
Reproduction, Eleventh Annual Report, 1982).
 
Home visiting pill 
 
Nine home visiting antifertility pills or vacation pills have been developed and used as 
post-coital or anti-implantation agents in the People’s Republic of China (Lei and Hu, 
1981); of these, anordrin (at a dose of 7·5 mg) apparently used as post-coital pill 
interferes with implantation by inhibition of luteal function and of endometrial 
development. It is not clear from the Chinese studies if anordrin was even used strictly 
as a post-coital pill. The antifertility activity of anordrin has been attributed to its 
antiestrogenic activity (Mehta et al., 1981), or to estrogenic acceleration of tubal 
transport or degeneration of eggs during tubal transport in the hamster (Gu and 
Chang, 1979). 
A number of attempts have been made to synthesize related compounds to dissociate 
the estrogenic activity from antifertility activity but none had yet reached the stage of 
clinical evaluation. 
 
Centchroman 
 
The biological and antifertility effects of centchroman (3,4-trans-2, 2-dimethyl-3- 
phenyl-4 p-(β-pyrrolidinoethoxy)-phenyl 7-methoxychroman have been investigated 
(Kamboj et al., 1977); the compound has weak estrogenic and potent anti-estrogenic 
activity; it is devoid of progestational androgenic and anti-androgenic properties but 
antagonises progesterone in the rabbit. Its antifertility activity in rats, dogs and 
monkeys may be due to its multiple hormone attributes such as estrogenic, anti- 
estrogenic and antiprogestational activities.
Phase II clinical studies have been carried out in post-coital (60 mg) and once-a-week
treatment schedules at doses of 120, 60, 30, 25, 20 and 15 mg. The results reported
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indicate that centchroman provides good protection against pregnancy at 30 mg and
other higher doses studied (Nitya Anand, personal communication). Ovarian and 
uterine enlargement was observed in both treatment regimes, with recovery to normal 
size within 30 days of withdrawal of the drug. Delay in menstruation of varying 
duration has also been reported. Since the doses used led to ovarian/uterine 
enlargement and irregular cycles, smaller doses (30 mg/week) are being evaluated 
clinically. As centchroman has been shown to induce release of luteinizing hormone 
(LH) in rats (Arabatti et al., 1977) the possibility of induction of ovulation as with 
clomiphene cannot be ruled out. The reported side effects on the ovary, uterus, and the 
irregular menstrual cycle caused by centchroman, call for further studies with much 
lower doses than used so far, before the hopes raised of the compound being used as a 
post-coital or once-a-week drug can be realized.
 
 
Evaluation of post-coital drugs 
 
Animal models 
 
A primary problem is the animal model for evaluation of post-coital drugs. By 
definition, such drugs should be evaluated for their efficacy by administration after 
mating. However, a post-coital drug can be tested in a rodent or non-human primate 
model only during the periovulatory period, when the females are sexually receptive 
and mate. Since mating does not occur at other times of the cycle, as is the case in the 
human, there is no possibility of testing the post-coital efficacy of drugs in any animal 
model by administration during periods of the menstrual/estrus cycle other than the 
periovulatory period. A possible, but tedious approach is to artificially inseminate 
laboratory rodents/non-human primates at other periods of the cycle and administer 
the drug to determine the side effects.
 
Toxicology 
 
There are no standard procedures set out for the toxicological evaluation of post-coital 
drugs in animals. The questions that need to be answered are (a) how many times in a 
month should the drug be administered, and (b) what should be the frequency of 
administration? For example, for levonorgestrel which is administered as a post-coital 
agent (Postinor) in Hungary, the maximum suggested intake is 4 tablets/month, i.e. 
750 µg/tablet, equivalent to a total dose of 3 mg/month. The question is, should the 
toxicology of such a drug be carried out by administering the test compound to animals 
(rodents or non-human primates) using the same schedule as would be applicable to the 
human, or should the drug be administered daily and, if so, for how long? This is true 
for evaluation of menses-inducing drugs also.
 
 
Problems associated with post-coital contraceptives 
 
Yuzpe (1979) has summarized very well the problems associated with post-coital 
contraceptive studies, as follows.
Ideally, post-coital evaluation studies should be carried out in randomized, double-
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blind fashion, with couples of proven fertility who will utilize the specific technique (or 
a placebo) once at mid-cycle only when the risk of pregnancy is at a maximum, and who 
will avoid coitus at all other times during that cycle. However, it is obvious that the 
ethical considerations of such studies make it difficult to obtain volunteers for this 
purpose. For this reason, studies are generally carried out upon women who are 
exposed at various times during the menstrual cycle. Thus, the number of women 
evaluated for a particular method must be sufficiently large to provide statistically 
significant data regarding efficacy. 
Studies which utilize patient volunteers whose admission to only one single act of 
unprotected coitus is necessary for study inclusion are at a disadvantage. Reliance upon 
the patient to take the entire dosage of prescribed medication also has its obvious 
disadvantages, especially if nausea and vomiting are common occurrences.
 
Risks of post-coital contraception
 
In the light of potential failure of this technique, back-up abortion facilities should be 
available. The true potential of the adverse effects of treatment failures is, as yet, not 
fully understood. Furthermore, failure in such instances should be considered as a 
method failure similar to pregnancy resulting from the failure of an IUD or other 
barrier method. 
 
Benefits of post-coital contraception 
 
The major value of post-coital contraception in countries like North America seems to 
be in the area of emergency treatment. The woman at risk of pregnancy from sexual 
assault or a single, unprotected coital exposure may be spared the emotional and 
physical trauma of unwanted pregnancy.
Once the purpose has been achieved, the patient may be counselled, and her choice of 
contraception made from one of the available methods. This choice, of course, depends 
upon patient motivation, coital frequency, socioeconomic status, as well as other 
sociologic variables.
Easily available post-coital contraception also has the potential of reducing the use 
and acceptability of cyclic oral contraception, IUDs and barrier methods which have 
proved so effective for millions of women. 
If a simple effective method of post-coital contraception is available, the woman may 
be spared the psychic trauma which is often associated with awaiting the passage of 
time in anticipation of the next expected menses.
 
Menses-inducing drugs 
 
There is great demand from women and from national family planning programmes for 
a simple and safe method of birth control for use when menses are delayed for a few 
days. The availability of such technology would limit exposure to fertility regulating 
methods only to such occasions when there is a probability of pregnancy. Moreover, if 
fertilization had indeed, occurred, interruption would take place at the earliest stage of 
pregnancy, thereby reducing the excessive bleeding encountered with later termination 
of pregnancy. 
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The only currently available methods of termination of very early pregnancy are
mechanical aspirators that in most instances require trained personnel. Experience with 
them indicates an efficacy of 95 % when used at five or six weeks since the last menstrual 
period. About 5% of patients have severe bleeding or retention of products of
pregnancy requiring vacuum aspiration. Uterine perforation rates are approximately 
equivalent to those at seven to eight weeks vacuum aspiration.
Menstrual regulation could be achieved by any one or more of the following 
approaches: 
 
—block progesterone receptors and interfere with the preparation of the endo- 
metrium for implantation; 
—luteolysis leading to decreased progesterone levels and interruption of pregnancy; 
—termination of early pregnancy by prostaglandins. 
 
A study comparing the efficacy and safety of two prostaglandin E2 analogues and 
vacuum aspiration for termination of very early pregnancy in women with a delay of 
menstruation of up to 14 days is ongoing at present in several countries (WHO Special 
Programme of Research in Human Reproduction, Eleventh Annual Report, 1982; 
1983). 
 
Progesterone receptor blockers —progesterone antagonists
 
Progesterone plays an indispensible role during the implantation phase and early 
pregnancy in animals and women; withdrawal of progesterone leads to breakdown of 
the secretory endometrium in the normal menstrual cycle. Likewise, the decidua which 
develops from the endometrium following implantation regresses and is shed in the 
absence of progesterone. There are several possible methods for interference with the 
secretion and action of progesterone. One of these is to block the action of progesterone 
on the endometrium. 
It has been demonstrated that progesterone receptors are generated during the 
follicular phase of the menstrual cycle reaching a maximum just before ovulation, after 
which they decline markedly (Bayard et al., 1975). During the luteal phase of the 
menstrual cycle, despite the decrease in the total concentration of progesterone 
receptors in the endometrial cells, there is an increase in their concentration in the 
cellular nuclei (Bayard et al., 1979; Levy et al., 1980). Early pregnancy endometrium 
(8–10 weeks gestation) is characterized by a large concentration of progesterone
receptors, exceeding those of any period in the menstrual cycle (Levy et al., 1980). A 
progesterone antagonist, or antiprogestin, taken orally during very early pregnancy or 
after missed menses could, by binding to endometrial progesterone receptors, interfere 
with the maintenance of the secretory endometrium essential for continuation of 
pregnancy. A number of compounds evaluated so far have shown either agonistic 
(progestational) and/or estrogenic activity.
The desired characteristics of a progesterone antagonist are that it should: (a) be 
orally active; (b) have a high affinity for progesterone receptors in the radio-receptor 
binding assay in competition with progesterone. There is no agreement on whether the 
ideal compound would bind rapidly and dissociate slowly or bind and dissociate 
rapidly; (c) have high antiprogestin and low progestin activity in the Clauberg test in
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rabbits, in deciduoma test in rats, in pregnancy maintenance test in rats and in the 
diamine oxidase assay; (d) have no or markedly reduced estrogenicity; (e) show 
significant anti-implantation effect in rats/hamsters/rabbits and non-human primates; 
and (f) be free from toxicological and teratological effects.
Over the past decade, attention has been directed towards understanding the 
molecular basis for the biological activity of progesterone in order to permit the 
development of an anti-progestational agent. Most of these efforts have been empirical. 
Investigators have examined the steroids that have progestational activity in the hope 
of defining the molecular requirements for activity and structural features that could be 
manipulated to alter the degree of response. It is now clear that knowledge of the 
structures of the progestins alone will not permit the development of an antiprogestin.
The WHO Task Force on Post-coital and Once-a-Month Drugs has embarked on 
the synthesis of new progesterone receptor blockers based on the study of the structure 
of the uterine progesterone receptor. The human endometrial progesterone receptor 
has been purified (Smith et al., 1982). Three active sites of the receptor have been 
identified by affinity labelling with 21-, 16- and 11-O3H bromo-acetoxyprogesterone; 
these three derivatives specifically bound to and displaced progesterone bound to the 
human endometrial progesterone receptor and migrated as a single protein band on 
Polyacrylamide gel electrophoresis of molecular weight 42,000 (Holmes et al., 1981).
A few questions which need to be answered are: 
What does the binding site look like? Exactly what happens to the site when 
progesterone binds to it? Do compounds with vastly different progestational activity 
trigger different degrees of change in the receptor? To what extent is the steroid buried 
in the receptors? Does part of the steroid control binding and another part control 
activity? Is the steroid partially exposed when bound to the receptor? Does this exposed 
part control activity by interaction with another macromolecule, histones, non- 
histones or DNA? Can we design a molecule that will fulfil the structural requirements 
for binding but fail to elicit the activating response?
The logical way to obtain answers to these questions is to determine the X-ray crystal 
structure of the progesterone receptor. Once the receptor protein has been crystallized, 
a series of steroidal and non-steroidal compounds can be examined to determine how 
they fit into the receptor site.
Thus the scientific rationale for such an approach for development of antiprogestins 
is clear. However, it does require large amounts of financial investment.
Herrmann et al. (1982) have described the use of a 19-nor testosterone derivative 
RU38486, 17α-propynyl-llß-(4-dimethyl-aminophenyl)-, 9,10-dihydro-19-nor testos- 
terone for induction of abortion and menses regulation. This compound has great 
affinity for the progesterone receptor without progestational, estrogenic or anti- 
estrogenic activity. It binds to glucocorticoid and human progesterone receptors. No 
toxic effects were seen during 30 days of administration to rats and monkeys except for 
those attributable to the antiglucocorticoid effects in high doses. When 200 mg/day of 
the compound was given, either in two or four divided doses to women who were 6–7·5 
weeks pregnant, abortion occurred in 8 of the 11 subjects in 3–8 days after the initiation
of treatment. Six women with normal menstrual cycles were administered 50 mg/day 
for four days between days 22–25 of the cycle and in all cases bleeding occurred within
48 h of treatment concurrent with a rapid fall in plasma progesterone and estradiol to
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follicular phase levels. No side effects were reported in any of the eight treatment cycles
and the subsequent menstrual cycles were apparently ovulatory as judged by basal 
body temperature. These results are highly encouraging in demonstrating clinical 
effectiveness of an antiprogestational agent. The WHO Special Programme in Human 
Reproduction is carrying out a dose finding study of the compound for termination of 
very early pregnancy (delayed menses) (WHO, 1983). Even as these clinical studies 
progress, attempts to synthesize even more potent and active progesterone antagonists 
continue based on a better understanding of the receptor binding sites of the human 
endometrial progesterone receptor.
The objective in the development of such compounds would be to use them regularly 
once-a-month for menstrual regulation or for termination of very early pregnancy.
 
Other compounds 
 
A possible anti-implantation agent is α-difluoromethylornithine which inhibits implant-
tation in rats when administered intraperitoneally at a dose of 200 mg/kg twice daily on 
day 4–7 of pregnancy (Reddy and Rukmini, 1981). It is also effective in rabbits (Fozzard
et al., 1980). The mechanism of action of the compound is by inhibition of ornithine 
decarboxylase enzyme and consequently the synthesis of putrescine, which is essential 
for embryogenesis (Fozzard et al., 1980). The compound is active in vivo and apparently 
non-toxic (Prakash et al., 1978). In view of the possible consequences of systemic 
inhibition of a ubiquitous enzyme like ornithine decarboxylase, the potential of its use 
for fertility regulation remains to be determined.
An anti-progesterone monoclonal antibody, has been shown to block, the establish- 
ment of pregnancy in mice, probably by interfering with the transport of the fertilized 
ovum along the fallopian tube when administered at 32 h post-coitum (PC) and 
interrupted implantation when injected 109–130 h PC (Wright et al., 1982); these effects 
were possibly due to reduction by the antiprogesterone antibody of readily available 
progesterone in circulation by more than 85 % during the critical phase of implantation. 
The acceptability and safety of a passive immunization method needs to be established 
before its use for inhibition of implantation. Passive immunization even with 
monospecific antibodies runs the risk of sensitizing the recipient to the foreign antibody 
protein. Although in theory this risk could be reduced by ‘typing’ the recipients and the 
clone products, this is unlikely to prove practical or entirely feasible for wide-scale 
application. Another way in which the risk of sensitization can be reduced is by the use 
of F(ab)2 fragments although this would add an expensive additional step in the 
preparation. Even if the intended use is as a monthly administration, or at less frequent 
intervals, the risk of sensitization would still remain.
 
Zoapatle 
 
Zoapatle, is the common name for Montanoa tomentosa, which grows in Mexico. 
Ethnobotanical studies and the clinical use of a number of constituents extracted from 
the plant have been reviewed recently (Gallegos, 1983); extracts from zoapatle have 
been shown to be uterotonic (Gallegos, 1983); bleeding occurred in four out of six 
subjects when administered at a dose of 100 g/day during early pregnancy (Landgren et 
al.,1979). Zoapatanol, however, which is obtained by total synthesis, has apparently no
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uterotonic effect (Smith et al., 1981). This discrepancy between the plant extract and the
pure synthetic compound needs to be resolved. A number of other chemical entities 
extracted from zoapatle such as kauradienoic acid, kaurenoic acid, zoapatlin and 
monoginoic acid need to be evaluated for their biological activity, in addition to 
continuation of studies with pure zoapatanol (Gallegos, 1983). The question that needs 
to be considered is whether optimal effects are produced by combination of one or 
more of the above constituents.
 
 
Interference with luteal function 
 
Normal corpus luteum function and secretion of progesterone are needed for 
implantation to occur and pregnancy to be established. Its function is directly under the 
control of pituitary gonadotropins and in a non-pregnant menstrual cycle the corpus 
luteum regresses within 10—12 days after ovulation. Human chorionic gonadotropin 
(hCG) secreted by the trophoblast of the developing and implanting blastocyst, rescues 
the corpus luteum from regression and maintains it.
 
hCG derivatives 
 
Attempts have been made to prepare derivatives of hCG which could act as antagonists 
of hCG for inhibition of luteal function. Such an hCG antagonist when administered 
after missed menses could competitively displace hCG bound to the corpus luteum 
leading to luteal regression, decreased progesterone levels, interruption of pregnancy 
and induction of menstrual-like bleeding (WHO Special Programme of Research in 
Human Reproduction, Annual Reports, 1979–1983). A number of derivatives of hCG
have been prepared and their physico-chemical characteristics and biological activities 
evaluated in vitro and in vivo. One of the derivatives, periodate oxidized–reduced
derivative, designated PORA-hCG which had lost all its galactosyl and 40 % of 
mannosyl residues, following sequential treatment with specific exoglycosidases has 
been evaluated (Bahl and Moyle, 1978). This derivative bound to the ovarian receptors 
with a 2·4 times higher affinity than hCG, caused a dose-dependent inhibition of the
action of hCG in production of cAMP by corpus luteal cells in vitro, had 2–5 % of
agonistic activity in stimulating progesterone production (Kalyan et al., 1982; 
Channing and Bahl, 1978a,b); PORA-hCG inhibited implantation in rats when 
administered subcutaneously at doses greater than 0·25 µg/day from days 1–5 PC
(Kalyan et al., 1981). However, one of the principal disadvantages is that the derivative 
is stable only at – 20°C in the lyophylized or solution form (Kalyan et al., 1982).
A different approach for the production of hCG antagonists has been reported by 
Manjanath and Sairam (1982) who have shown that treatment of purified hCG with 
anhydrous hydrogenfluoride (HF) at 0°C for 60 min removed 75% carbohydrate 
without affecting the peptide moiety. The O-glycosidically-linked glycopeptide part in 
the C-terminal peptide of the α-subunit was least affected by treatment. De- 
glycosylation reduced heterogenicity that is inherent to native hCG. Its solubility was 
not affected. The product was obtained in good yield in a stable and lyophilized form. 
Even the most drastic conditions could not remove all of the carbohydrate; this may 
even lead to reduction of receptor binding and antagonistic activities. In cell receptor
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binding assays, viz. rat testis, pseudopregnant rat ovary, porcine granulosa cell, rhesus
monkey testis, deglycosylated (DG) hCG showed approximately 200% activity as 
compared to native hCG. There was no reduction in immunological activity of DG 
hCG as tested by radioimmunoassay using [125I]-hCG and an antibody to native hCG. 
As against full agonistic activity in receptor binding, DG hCG almost completely lost 
its activity in responsive cells incubated in vitro. Both cyclic AMP accumulation and 
testosterone synthesis caused by native hCG were inhibited by the concomitant 
presence of DG hCG (Sairam, 1982).
DG hCG is heat stable. Significant receptor binding, immunological and hormonal 
antagonistic properties are retained by DG hCG after exposure in a boiling water bath. 
This may contribute to the long shelf life of the antagonist in aqueous solutions; it is 
stable in the lyophilized form at 4°C for up to 12–16 months (Sairam and Manjanath, 
1983). DG hCG has been shown to inhibit implantation when administered subcu- 
taneously at a dose of 50 µg/day from days 1–5 PC; similar doses administered between
days 8–11 of pregnancy resulted in complete termination of pregnancy and foetal
resorption accompanied by a fall in serum progesterone levels. The derivative had little 
effect on pregnancy, foetal growth or parturition when administered from days 13–16
(Kato et al., 1983). 
A number of issues that need to be studied before these derivatives may be considered 
for use in termination of early pregnancy are: (a) immunogenicity of DG hCG; 
(b) antifertility effects in non-human primates; (c) alternate methods of derivative 
production; and (d) delivery system and mode and route of administration.
 
 
Evaluation of menses-inducing drugs 
 
The efficacy of menses-inducing drugs (anti-progestins or luteolytic agents) can be 
evaluated in non-human primates in which pregnancy can be determined accurately by 
timed mating. Reproductive profiles and standard criteria for the choice of females for 
such studies have been reported for the rhesus monkey, bonnet monkey and the 
baboon (Anand Kumar et al., 1980; Hendrickx and Enders, 1980; Murthy et al., 1980). 
The test drugs are administered on days 22–24 of the menstrual cycle in animals in
which pregnancy is established by monitoring levels of chorionic gonadotropin and the 
effects evaluated by termination of pregnancy, onset of menstrual bleeding and 
decrease in serum levels of chorionic gonadotropin to non-detectable levels.
The luteolytic activity of compounds can also be evaluated in monkeys by 
administration of the compound during the luteal phase of non-pregnant rhesus 
monkeys (Ricardo et al., 1982). One of the principal disadvantages in these studies is the 
short luteal phase. If the functional life of the corpus luteum of a non-pregnant cycle 
can be prolonged for 10–15 days by administration of hCG, it should provide a suitable 
model to evaluate the efficacy of luteolytic agents. Such studies are in progress in the 
bonnet monkey (WHO 1982).
 
 
Research on implantation in non-human primates 
 
Development of primate models: There are a number of gaps in the knowledge of the 
processes regulating implantation which need to be investigated. Some of these are:
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—hormonal profiles during the periimplantation period
—changes in the concentration of progesterone and estrogen receptors during the
periimplantation and post-implantation periods;
—hormonal requirements for ovum implantation; 
—changes in histochemistry of the endometrium during implantation: whether there
are any enzymes which are crucial to the initiation of implantation;
—role of the blastocyst in initiating metabolic and cellular changes in the
endometrium at the time of implantation;
—whether the functional life of the corpus luteum of a non-pregnant menstrual cycle
can be prolonged by hCG administration, if so, for how long? Such a model would
be useful for screening luteolytic agents. 
 
These studies could provide new leads for evaluation and development of new anti- 
implantation agents which could be used either PC or for menses-induction. There is no 
agreement on the appropriate primate species to be used for thses studies. Such studies 
should be carried out in a range of  primate species and not concentrated on the few on 
which data is currently available, since it is most unlikely that any one species will prove 
ideal as a model for all aspects of implantation in the human. There are also other 
factors on the availability, cost, ease of management, breeding performance in captivity.
That might affect their choice for achieving different goals in research on implantation.
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